Investigation of Sensitivity to AZD7762 in TripleNegative Breast Cancer (TNBC) with RBFOX2 Gene Expression as a Biomarker

Objective: Triple negative breast cancer (TNBC) is one of the most metastatic, aggressive with poor prognosis types cancers. There currently no standard molecular-targeted treatment for TNBC. Therefore, new therapeutics should be developed. The aim this study was to determine effect AZD7762 on several cell lines and evaluate RBFOX2 gene expression levels as a marker show sensitivity drug. Materials Methods: cytotoxic determined by sulforhodamine B method. were quantitative real-time polymerase chain reaction (qRT-PCR). association between IC50 values selected drug evaluated using Pearson r correlation analysis. Results: Although there significant difference TNBC non-TNBC groups, it that tended more sensitive AZD7762. In addition, obvious increasing detected in cells showed Conclusion: It concluded can used biomarker efficiency. Further studies are needed investigate potential signaling mechanisms associated